JPWO2021077806A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021077806A5 JPWO2021077806A5 JP2021537127A JP2021537127A JPWO2021077806A5 JP WO2021077806 A5 JPWO2021077806 A5 JP WO2021077806A5 JP 2021537127 A JP2021537127 A JP 2021537127A JP 2021537127 A JP2021537127 A JP 2021537127A JP WO2021077806 A5 JPWO2021077806 A5 JP WO2021077806A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding
- peptide linker
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911015236.1 | 2019-10-24 | ||
| CN201911015236.1A CN110669137B (zh) | 2019-10-24 | 2019-10-24 | 一种多特异性抗体及其制备方法和用途 |
| PCT/CN2020/100892 WO2021077806A1 (zh) | 2019-10-24 | 2020-07-08 | 一种多特异性抗体及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553464A JP2022553464A (ja) | 2022-12-23 |
| JPWO2021077806A5 true JPWO2021077806A5 (ko) | 2023-07-19 |
Family
ID=69083964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537127A Pending JP2022553464A (ja) | 2019-10-24 | 2020-07-08 | 多重特異性抗体とその製造方法および使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210388077A1 (ko) |
| EP (1) | EP3868788A4 (ko) |
| JP (1) | JP2022553464A (ko) |
| KR (1) | KR20220087402A (ko) |
| CN (2) | CN113416258B (ko) |
| AU (1) | AU2020371001A1 (ko) |
| WO (1) | WO2021077806A1 (ko) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113416258B (zh) * | 2019-10-24 | 2023-08-29 | 北京免疫方舟医药科技有限公司 | 一种多特异性抗体及其制备方法和用途 |
| CN113214406B (zh) * | 2020-01-21 | 2022-08-02 | 苏州普乐康医药科技有限公司 | 一种结合gpc3融合蛋白的制备方法及应用 |
| CN112336873B (zh) | 2020-08-04 | 2022-04-19 | 华南理工大学 | 用于多特异性抗体递送的蛋白型纳米颗粒及其应用、制备方法 |
| CN113527503A (zh) * | 2021-07-27 | 2021-10-22 | 福建医科大学 | 一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白 |
| CN114409797B (zh) * | 2021-12-24 | 2024-02-20 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
| CN116640224A (zh) * | 2022-02-16 | 2023-08-25 | 北京免疫方舟医药科技有限公司 | Cd137抗体和cd40l的融合蛋白及其应用 |
| CN114380917B (zh) * | 2022-03-25 | 2022-06-14 | 南京融捷康生物科技有限公司 | 针对IL-17A和TNFα的双特异性单域抗体及其用途 |
| WO2024067474A1 (zh) * | 2022-09-29 | 2024-04-04 | 上海宏成药业有限公司 | 靶向pd-1，ctla-4和vegf的三特异性抗体及其应用 |
| CN115969997B (zh) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | 一种靶向cldn18.2的抗体药物偶联物及其应用 |
| CN116987198B (zh) * | 2023-09-28 | 2023-12-26 | 军科正源（北京）药物研究有限责任公司 | 一种靶向人pd-l1的融合蛋白及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| AU2238292A (en) * | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| CN1842538B (zh) * | 2003-06-27 | 2013-06-12 | 比奥根艾迪克Ma公司 | 包含连接肽的修饰的结合分子 |
| WO2009138519A1 (en) * | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| CN101842387B (zh) * | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| RU2617970C2 (ru) * | 2011-08-23 | 2017-04-28 | Рош Гликарт Аг | Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения |
| EP2748202B1 (en) | 2011-08-23 | 2018-07-04 | Roche Glycart AG | Bispecific antigen binding molecules |
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| MX2016008667A (es) | 2013-12-30 | 2017-02-02 | Epimab Biotherapeutics Inc | Inmunoglobulina con fab en tandem y usos de esta. |
| CN107172880B (zh) * | 2014-03-24 | 2021-09-28 | 癌症研究技术有限公司 | 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途 |
| GB201409558D0 (en) * | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| EP3164417A1 (en) * | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| CN104592392B (zh) * | 2015-01-21 | 2018-08-28 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
| WO2016097313A1 (en) * | 2014-12-19 | 2016-06-23 | Ablynx N.V. | Cysteine linked nanobody dimers |
| CN104558191B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd20×cd3的构建及应用 |
| GB201521393D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
| RU2018141777A (ru) * | 2016-04-28 | 2020-05-28 | Биомюнё Фармасьютикалз | Биспецифичные антитела, нацеленные на egfr и her2 |
| CN108367075B (zh) | 2016-11-23 | 2022-08-09 | 免疫方舟医药技术股份有限公司 | 4-1bb结合蛋白及其用途 |
| CN107266567B (zh) * | 2017-06-05 | 2021-06-04 | 高新 | Lcrmp4单克隆抗体及其制备方法与应用 |
| CN113416258B (zh) * | 2019-10-24 | 2023-08-29 | 北京免疫方舟医药科技有限公司 | 一种多特异性抗体及其制备方法和用途 |
-
2019
- 2019-10-24 CN CN202110525473.3A patent/CN113416258B/zh active Active
- 2019-10-24 CN CN201911015236.1A patent/CN110669137B/zh active Active
-
2020
- 2020-07-08 EP EP20878020.5A patent/EP3868788A4/en active Pending
- 2020-07-08 AU AU2020371001A patent/AU2020371001A1/en active Pending
- 2020-07-08 WO PCT/CN2020/100892 patent/WO2021077806A1/zh unknown
- 2020-07-08 KR KR1020217015906A patent/KR20220087402A/ko unknown
- 2020-07-08 JP JP2021537127A patent/JP2022553464A/ja active Pending
- 2020-07-08 US US17/292,739 patent/US20210388077A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021077806A1 (zh) | 一种多特异性抗体及其制备方法和用途 | |
| US20210196821A1 (en) | Multimeric il-15-based molecules | |
| US11459394B2 (en) | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof | |
| CA3089333C (en) | Anti-pdl1, il-15 and tgf-beta receptor combination molecules | |
| JP7348899B2 (ja) | 多重特異性分子及びその使用 | |
| JP6936497B2 (ja) | 多価Ｆｖ抗体 | |
| CA3036564A1 (en) | Multispecific antibody molecules comprising lambda and kappa light chains | |
| TW202012441A (zh) | Nk細胞接合抗體融合構築體 | |
| KR20210091710A (ko) | PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도 | |
| MX2014000816A (es) | Molecula fv de union de antigeno multivalente. | |
| CA3201573A1 (en) | Targeted cytokine construct for engineered cell therapy | |
| JP2022549186A (ja) | 高い標的密度の細胞に対する選択性を向上させた多量体抗体 | |
| CA3059769A1 (en) | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof | |
| CA3113826A1 (en) | Csf1r/ccr2 multispecific antibodies | |
| JPWO2021077806A5 (ko) | ||
| WO2022100652A1 (zh) | 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途 | |
| US20230322952A1 (en) | Multispecific antibodies that bind both mait and tumor cells | |
| JP2023539645A (ja) | Ｎｋｐ３０に結合する抗体分子およびその使用 | |
| US11739145B2 (en) | Bispecific binding agents binding to CLDN18.2 and CD3 | |
| US20230295348A1 (en) | Composition and methods for the selective activation of cytokine signaling pathways | |
| CN117003884A (zh) | 一种多靶向融合蛋白Rainbody及其制备方法和用途 |